Gemtuzumab ozogamicin (CAT#: TP-107CL)
Recombinant humanized IgG4, kappa antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin, isolated from fermentation of a bacterium, Micromonospora echinospora ssp. calichensis. The antibody portion of Mylotarg binds specifically to the CD33 antigen, The anti-CD33 hP67.6 antibody is produced by mammalian cell suspension culture using a myeloma NS0 cell line. Gemtuzumab ozogamicin (trade name Mylotarg) was withdrawn in 2010 when a clinical trial showed the drug increased patient death and exhibited no advantages over traditional cancer therapies.
Isotype: Biotech
Specific Inquiry
Specifications
- Type
- Biotech
- Trade name
- Mylotarg
- UNII
- 8GZG754X6M
Target
- Function
- Humanized anti-CD33 IgG4k mAb conjugated to calicheamicin, a small-molecule chemotherapeutic agent
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
Customer Reviews and Q&As
Submit a review or a question
There are currently no Customer reviews or questions for TP-107CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
* Abbreviations
AgonistAgonist
BABioassay
InhibInhibition
PGProteogenomics
StimStimulation
WBWestern Blot
Send Inquiry
© 2023 Creative BioLabs. All Rights Reserved